Cutaneous Side Effects of Antiosteoporosis Treatments

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 1, 2011, Pages 31-41

  Musette, Philippe ^a   Kaufman, Jean Marc ^b   Rizzoli, René ^c   Cacoub, Patrice ^d   Brandi, Maria Louisa ^e   Reginster, Jean Yves ^f  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

antiosteoporosis treatments; cutaneous adverse reactions; hypersensitivity reactions; osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; AMIODARONE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CEPHALOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMOLLIENT AGENT; LAMOTRIGINE; NEUROLEPTIC AGENT; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; STRONTIUM RANELATE; SULFANILAMIDE; SULFONAMIDE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; HUMAN; MACULOPAPULAR RASH; OSTEOARTHRITIS; OSTEOPOROSIS; PHOTOALLERGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 79955389290     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X10387202     Document Type: Review

References (58)

1. Aberer W. Kranke B. (2008) Clinical manifestations and mechanisms of skin reactions after systemic drug administration. Drug Discovery Today 5: e237–e247.
2. Allanore L. Roujeau J.C. (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis. In: Ed. Pichler W.J. (ed.) Drug Hypersensitivity. Basel: Karger, pp. 267–277.
3. Autier P. Haentjens P. Bentin J. Baillon J.M. Grivegnee A.R. Closon M.C. et al (2000) Costs induced by hip fractures: A prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11: 373–380.
4. Barrera B.A. Wilton L. Harris S. Shakir S.A. (2005) Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int 16: 1989–1998.
5. Belhadjali H. Slim R. Aouam K. Youssef M. Zili J. (2008) Cutaneous vasculitis induced by risedronate. Allergy 63: 1405.
6. Bigby M. (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137: 765–770.
7. Biswas P.N. Wilton L.V. Shakir S.A. (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507–514.
8. Bliuc D. Nguyen N.D. Milch V.E. Nguyen T.V. Eisman J.A. Center J.R. (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513–521.
9. Boada A. Carrascosa J.M. Leal L. Ferrandiz C. (2009) Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 23: 321–322.
10. Bocquet H. Bagot M. Roujeau J.C. (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15: 250–257.
11. Borchers A.T. Lee J.L. Naguwa S.M. Cheema G.S. Gershwin M.E. (2008) Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7: 598–605.
12. Brinkmeier T. Kugler K. Lepoittevin J.P. Frosch P.J. (2007) Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57: 123–125.
13. Burnett-Bowie S.A. (2008) Is twice-yearly denosu-mab beneficial in postmenopausal women with osteo-penia but no history of fracture? Nat Clin Pract Endocrinol Metab 4: 660–661.
14. Center J.R. Nguyen T.V. Schneider D. Sambrook P.N. Eisman J.A. (1999) Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353: 878–882.
15. Chrischilles E. Shireman T. Wallace R. (1994) Costs and health effects of osteoporotic fractures. Bone 15: 377–386.
16. Chung W.H. Hung S.I. Hong H.S. Hsih M.S. Yang L.C. Ho H.C. et al (2004) Medical genetics: A marker for Stevens–Johnson syndrome. Nature 428: 486.
17. Cooper C. Atkinson E.J. Jacobsen S.J. O'Fallon W.M. Melton L.J. 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137: 1001–1005.
18. Edwards I.R. Aronson J.K. (2000) Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356: 1255–1259.
19. Eshki M. Allanore L. Musette P. Milpied B. Grange A. Guillaume J.C. et al (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: A cause of unpredictable multiorgan failure. Arch Dermatol 145: 67–72.
20. EMA (2007 a) Ibandronate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
21. EMA (2007 b) Parathyroid Hormone. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
22. EMA (2008 a) Alendronate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
23. EMA (2008 b) Zoledronic Acid. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
24. EMA (2008 c) Strontium Ranelate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
25. EMA (2008 d) Raloxifene. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (Accessed 11 February 2009).
26. EMA (2008 e) Teriparatide. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (Accessed 11 February 2009).
27. Faye O. Roujeau J.C. (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): Clinical experience to date. Drugs 65: 2085–2090.
28. FDA (2002) Risedronate. Description. US Food and Drug Administration. Available at: http://www.fda.gov (accessed 11 February 2009).
29. FDA (2009) Pharmapendium. US Food and Drug Administration. Available at: www.pharmapendium.com (accessed 23 February 2009).
30. Ghislain P.D. Roujeau J.C. (2002) Treatment of severe drug reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8: 5.
31. Gomes E.R. Demoly P. (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5: 309–316.
32. Grosso A. Douglas I. Hingorani A. MacAllister R. Smeeth L. (2008) Post-marketing assessment of the safety of strontium ranelate: A novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66: 689–694.
33. Groves C. (2008) Interstitial granulomatous reaction to strontium ranelate. Arch Dermatol 144: 268–269.
34. High W.A. Cohen J.B. Wetherington W. Cockerell C.J. (2003) Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. J Am Acad Dermatol 48: 945–946.
35. Hung S.I. Chung W.H. Liou L.B. Chu C.C. Lin M.J. Huang H.P. et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102: 4134–4139.
36. Hunziker T. Kunzi U.P. Braunschweig S. Zehnder D. Hoigne R. (1997) Comprehensive hospital drug monitoring (CHDM): Adverse skin reactions, a 20-year survey. Allergy 52: 388–393.
37. Jonville-Bera A.P. Crickx B. Aaron L. Hartingh I. Autret-Leca E. (2009) Strontium ranelate-induced DRESS syndrome: First two case reports. Allergy 64: 658–659.
38. Kimura M. Kawada A. Murayama Y. Murayama M. (2003) Drug eruption due to alendronate sodium hydrate. Contact Dermatitis 48: 116.
39. Kontoleon P. Ilias I. Stavropoulos P.G. Papapetrou P.D. (2000) Urticaria after administration of alendronate. Ada Derm Venereol 80: 398.
40. Layton D. Clarke A. Wilton L.V. Shakir S.A. (2005) Safety profile of raloxifene as used in general practice in England: Results of a prescription-event monitoring study. Osteoporos Int 16: 490–500.
41. Lazarov A. Moss K. Plosk N. Cordoba M. Baitelman L. (2002) Alendronate-induced lichen planus. Isr Med Assoc J 4: 389–390.
42. Lee H.Y. Lie D. Lim K.S. Thirumoorthy T. Pang S.M. (2009) Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 20: 161–162.
43. Mallal S. Phillips E. Carosi G. Molina J.M. Workman C. Tomazic J. et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358: 568–579.
44. McClung M.R. Lewiecki E.M. Cohen S.B. Bolognese M.A. Woodson G.C. Moffett A.H. et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831.
45. Mockenhaupt M. (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs, In: Ed. Pichler W.J. (ed.). Drug Hypersensitivity, Karger: Basel, pp. 18–31.
46. Mockenhaupt M. Viboud C. Dunant A. Naldi L. Halevy S. Bouwes-Bavinck J.N. et al (2008) Stevens–Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128: 35–44.
47. Morison W.L. (2004) Clinical practice. Photosensitivity. N Engl J Med 350: 1111–1117.
48. Pernicova I. Middleton E.T. Aye M. (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19: 1811–1812.
49. Rizos E.C. Milionis H.J. Elisaf M.S. (2006) Fever with rash following zolendronic acid administration. Clin Exp Rheumatol 24: 455.
50. Roujeau J.C. (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209: 123–129.
51. Schnyder B. Pichler W.J. (2009) Mechanisms of drug-induced allergy. Mayo Clin Proc 84: 268–272.
52. Shiohara T. Inaoka M. Kano Y. (2006) Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int 55: 1–8.
53. Shiohara T. Takahashi R. Kano Y. (2007) Drug-induced hypersensitivity syndrome and viral reactivation, In: Ed. Pichler W.J. (ed.). Drug Hypersensitivity, Karger: Basel, pp. 251–266.
54. Svensson C.K. Cowen E.W. Gaspari A.A. (2001) Cutaneous drug reactions. Pharmacol Rev 53: 357–379.
55. Valeyrie-Allanore L. Sassolas B. Roujeau J.C. (2007) Drug-induced skin, nail and hair disorders. Drug Saf 30: 1011–1030.
56. Viard I. Wehrli P. Bullani R. Schneider P. Holler N. Salomon D. et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science 282: 490–493.
57. Vidal L. (2009) Le Dictionnaire, 85th edn, Issy-les-Moulineaux, France: Vidal.
58. Wolf R. Orion E. Marcos B. Matz H. (2005) Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23: 171–181.